New agents are awaited for the treatment of multiple myeloma and research is 
ongoing for the development of monoclonal antibodies (MoAbs) targeting the tumor 
cells. One of the most promising MoAb is elotuzumab, the only humanized IgG1 
MoAb specifically targeting CS1 (SLAMF7), a cell surface glycoprotein that is 
highly expressed in plasma cells. Preclinical and clinical data on elotuzumab 
will be presented in this article.